201 related articles for article (PubMed ID: 30312198)
1. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.
Tsai S; George B; Wittmann D; Ritch PS; Krepline AN; Aldakkak M; Barnes CA; Christians KK; Dua K; Griffin M; Hagen C; Hall WA; Erickson BA; Evans DB
Ann Surg; 2020 Apr; 271(4):740-747. PubMed ID: 30312198
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer.
Aldakkak M; Christians KK; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Evans DB; Tsai S
HPB (Oxford); 2015 Oct; 17(10):942-52. PubMed ID: 26255895
[TBL] [Abstract][Full Text] [Related]
3. Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease.
Abdel-Misih SR; Hatzaras I; Schmidt C; Saab TB; Klemanski D; Muscarella P; Melvin WS; Ellison EC; Bloomston M
Ann Surg Oncol; 2011 Apr; 18(4):1116-21. PubMed ID: 21042945
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis.
Ye C; Sadula A; Ren S; Guo X; Yuan M; Yuan C; Xiu D
Cancer Chemother Pharmacol; 2020 Dec; 86(6):731-740. PubMed ID: 33047181
[TBL] [Abstract][Full Text] [Related]
5. Value of Pretreatment
Barnes CA; Aldakkak M; Clarke CN; Christians KK; Bucklan D; Holt M; Tolat P; Ritch PS; George B; Hall WA; Erickson BA; Evans DB; Tsai S
Front Oncol; 2020; 10():500. PubMed ID: 32363161
[No Abstract] [Full Text] [Related]
6. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity.
Thalji SZ; Aldakkak M; Christians KK; Clarke CN; George B; Kamgar M; Erickson BA; Hall WA; Chisholm P; Kulkarni N; Doucette S; Evans DB; Tsai S
J Surg Oncol; 2023 Jul; 128(1):41-50. PubMed ID: 36960919
[TBL] [Abstract][Full Text] [Related]
8. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
[TBL] [Abstract][Full Text] [Related]
9. Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer.
Martin LK; Wei L; Trolli E; Bekaii-Saab T
Med Oncol; 2012 Dec; 29(5):3101-7. PubMed ID: 22729400
[TBL] [Abstract][Full Text] [Related]
10. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
[TBL] [Abstract][Full Text] [Related]
11. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis.
Okada K; Murakami Y; Uemura K; Kondo N; Nakagawa N; Seo S; Otsuka H; Takahashi S
Langenbecks Arch Surg; 2020 Aug; 405(5):623-633. PubMed ID: 32592044
[TBL] [Abstract][Full Text] [Related]
14. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer.
Liu H; Zenati MS; Rieser CJ; Al-Abbas A; Lee KK; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
Ann Surg Oncol; 2020 Oct; 27(10):3950-3960. PubMed ID: 32318949
[TBL] [Abstract][Full Text] [Related]
15. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer.
Miura JT; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Oshima K; Christians KK; Evans DB; Tsai S
Surgery; 2015 Dec; 158(6):1545-55. PubMed ID: 26243342
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first.
DiPeri TP; Newhook TE; Prakash LR; Ikoma N; Maxwell JE; Kim MP; Lee JE; Katz MHG; Tzeng CD
J Surg Oncol; 2022 Nov; 126(6):1021-1027. PubMed ID: 35726394
[TBL] [Abstract][Full Text] [Related]
17. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma.
Pendurthi TK; Hoffman JP; Ross E; Johnson DE; Eisenberg BL
Am Surg; 1998 Jul; 64(7):686-92. PubMed ID: 9655283
[TBL] [Abstract][Full Text] [Related]
18. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma.
Newhook TE; Vreeland TJ; Griffin JF; Tidwell RSS; Prakash LR; Koay EJ; Ludmir EB; Smaglo BG; Pant S; Overman M; Wolff RA; Ikoma N; Maxwell J; Kim MP; Lee JE; Katz MHG; Tzeng CD
Ann Surg; 2023 Mar; 277(3):484-490. PubMed ID: 36649067
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
20. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
